On average, a general practitioner, who works with an average practice list size of 6000 people, will look after 30 patients with chronic heart failure and suspect a new diagnosis of heart failure in approximately 10 patients annually.
Get full access to this article
View all access options for this article.
References
1.
British National Formulary. Accessed via www.bnf.org.uk.
2.
ChambersJ.Echocardiography in clinical practice (2002) New York, USA Parthenon Publishing Group ISBN 1–84214-108–2.
3.
ClelandJ.G.DaubertJ.C.ErdmannE.Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. European Heart Journal (2006) 27: p. 1928.
4.
DaviesM.K.HobbsF.D.R.DavisR.C.Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: A population based study. Lancet (2001) 358: p. 439–44.
HjalmarsonA.GoldsteinS.FagerbergB.Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. Journal of the American Medical Association (2000) 283 (10): p. 1295–302.
8.
KrumH.Beta-blockers in heart failure. The ‘new wave’ of clinical trials. Drugs (1999) 58 (2): p. 203–10.
9.
MillaneTJacksonG.ABC of heart failure, acute and chronic management strategies. British Medical Journal (2000) 320: p. 559–62.
PackerM.BristowM.R.CohnJ.N.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New England Journal of Medicine (1996) 334: p. 1349–55.
12.
PackerM.CoatsA.J.S.FowlerM.B.Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine (2001) 344: p. 1651–8.
13.
PittB.Poole-WilsonP.A.SegalR.Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial the Losartan Heart Failure Survival Study, ELITE II. Lancet (2000) 355: p. 1582–1587.
14.
PittB.SegalR.MartinezF.A.P.C.NeyD.E.Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349: p. 747–52.
15.
PittB.ZannadF.RemmeW.J.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine (1999) 341: p. 709–17.
16.
RCGPInformation sheet number No 4. General practice in the UK: A basic overview. (2005) Accessed via www.rcgp.org.uk/pdf/ISS_INFO_04_MAY05.pdf [date last accessed 08.10.2008].
SwedbergK.KjekshusJ.Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). American Journal of Cardiology (1988) 62 (2): p. 60A–66A.
19.
The CIBIS-II Investigators and Committees.The Cardiac Insufficiency Bisoprolol study 2 (CIBIS-II): A randomised trial. Lancet (1999) 353: p. 9–13.
20.
The Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine (1997) 336: p. 525–33.
21.
YoungJ.B.AbrahamW.T.SmithA.L.Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD trial. Journal of the American Medical Association (2003) 289: p. 2685.
